DSpace Repository

Covid-19 Tedavisinde İmmun Plazma Uygulamaları

Show simple item record

dc.creator NURLU TEMEL, Esra; SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ
dc.date 2021-06-05T00:00:00Z
dc.date.accessioned 2021-12-03T11:47:02Z
dc.date.available 2021-12-03T11:47:02Z
dc.identifier https://dergipark.org.tr/tr/pub/sdutfd/issue/62643/906321
dc.identifier 10.17343/sdutfd.906321
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/94225
dc.description Yüzyılda bir yaşanan ve ne zaman sonlanacağı öngörülemeyen şiddetli akut solunum yolu sendromu koronavirüsü-2 (SARS-CoV-2) pandemisi tüm dünyada hız kesmeden devam etmektedir. Umut verici aşı ve ilaç çalışmalarına rağmen pandeminin kontrol altına alınamaması nedeni ile iyileşen hastalardan elde edilen immun plazmanın koronavirüs hastalığı 2019 (COVID-19) tedavisinde uygulanması, alternatif tedavi seçeneklerinden biri olarak güncelliğini korumaktadır. İyileşen hasta plazmalarının salgın hastalıklarda kullanımı yeni bir yöntem olmayıp tarihte birçok bulaşıcı hastalığın tedavisinde kullanılmıştır. İmmun plazma içinde bulunan Nötralizan antikorların (Nab) bilinen etki mekanizması virusun hücre içine girişinin, füzyonunun ve çıkışının engellenmesidir. Plazma tedavisinin erken dönemde (7 gün) kullanılmasının hastalık şiddetini azaltarak hem hastanede kalış süresini kısalttığını hem de sağ kalımı arttırdığını gösteren çalışmalar mevcuttur. Güvenlik ile ilişkili olarak biriken veriler; immun plazma tedavisinin diğer plazma ürünleri ile benzer yan etkilere sahip olduğu yönündedir. İmmun plazmanın, duyarlı kişilerde doğrudan SARS-CoV-2’yi hedefleyebilecek etkili ve hızlı bir tedavi stratejisi olabileceği düşünülmektedir . Bu derlemede güncel veriler ışığında COVID-19 pandemisinde hızla kullanım alanı bulan plazma tedavisi uygulamaları tartışılacaktır.
dc.description The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, which is experienced once in a century and whose end is unpredictable, continues unabated around the world. Despite promising vaccine and drug studies, since the pandemic cannot be controlled, immune plasma continues to be up-to-date as one of the alternative treatment options in the treatment of coronavirus disease 2019 (COVID-19). The use of healed patient plasma in epidemic diseases is not a new method but has been used in the treatment of many infectious diseases in history. The known mechanism of action of neutralizing antibodies (Nab) in the immune plasma is to prevent the entry, fusion, and exit of the virus into the cell. Studies are showing that the use of plasma therapy in the early period (
dc.format application/pdf
dc.language tr
dc.publisher Süleyman Demirel Üniversitesi
dc.publisher Süleyman Demirel University
dc.relation https://dergipark.org.tr/tr/download/article-file/1672848
dc.source Volume: COVID-19 Özel Sayı, Issue: 1 87-92 en-US
dc.source 1300-7416
dc.source 2602-2109
dc.source SDÜ Tıp Fakültesi Dergisi
dc.subject Konvelesan Plazma,COVID-19,antikor,SARS-CoV-2,transfüzyon
dc.subject Convalescent plasma,COVID-19,antibody,SARS-CoV-2,transfusion
dc.title Covid-19 Tedavisinde İmmun Plazma Uygulamaları tr-TR
dc.title Immune Plasma Applications in Covid-19 Treatment en-US
dc.type info:eu-repo/semantics/article
dc.citation 1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51
dc.citation 2. Winau F Winau R. Emil von Behring and serum therapy. microbes and Infection 2002; 4:185-8.
dc.citation 3. Zingher A. Convalescent Whole Blood, Plasma and Serum In Prophylaxis Of Measles. JAMA.1924;82(15):1180–87.
dc.citation 4. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599-609.
dc.citation 5. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676-8.
dc.citation 6. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1.
dc.citation 7. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-56.
dc.citation 8. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva, Switzerland: WHO, 2014.
dc.citation 9. Tiberghien, Pierre et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox sanguinis 2020;115(6): 488-94.
dc.citation 10. Joyner MJ, Senefeld JW, Klassen SA, MillsJR, Johnson PW, Theel ES, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. Preprint. medRxiv.2020;2020.08.12.20169359.
dc.citation 11. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-24-2020
dc.citation 12. T.C Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Kan ve Kan Ürünleri Dairesi Başkanlığı COVID-19 İmmün (Konvalesan) Plazma Tedarik ve Klinik Kullanım Rehberi. 2020,Ankara.
dc.citation 13. https://www.aa.com.tr/tr/koronavirus/turkiyede-ilk-plazma-tedavisi-uygulanan-kovid-19-hastasi-iyilesti/1821009
dc.citation 14. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384(11):1015-1027.
dc.citation 15. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115-119.
dc.citation 16. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20(6):339-341.
dc.citation 17. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
dc.citation 18. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-2765.
dc.citation 19. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226-36.
dc.citation 20. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol .2020;(17):613–20.
dc.citation 21. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody re-sponses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their im-plications. MedRxiv 2020.https://doi.org/10.1101/2020.03.30.20047365.
dc.citation 22. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38.
dc.citation 23. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev. 1994;139:5-19.
dc.citation 24. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi LI, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003;9(4):431-8.
dc.citation 25. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537.
dc.citation 26. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-45.
dc.citation 27. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang Jet al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70.
dc.citation 28. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020;95(9):1888-97.
dc.citation 29. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data
dc.citation 30. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/overview-of-covid-19-interventions-v4.1.0.pdf
dc.citation 31. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021;325(12):1185-1195.
dc.citation 32. https://shgm.saglik.gov.tr/TR-65033/covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberi-yayinlanmistir.html
dc.citation 33. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496.
dc.citation 34. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890-1901.
dc.citation 35. Benjamin, R.J. and McLaughlin, L.S. (2012), Plasma components: properties, differences, and uses. Transfusion, 52: 9S-19S. https://doi.org/10.1111/j.1537-2995.2012.03622.x
dc.citation 36. https://shgmkanhizmetleridb.saglik.gov.tr/TR-76536/covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberi-guncellendi.html
dc.citation 37. Taşkın G. İmmün plazma tedavisi. Yamanel HL, editör. Yoğun Bakım ve COVID-19. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.103- 7.
dc.citation 38. Okba N, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-1488. https://dx.doi.org/10.3201/eid2607.200841
dc.citation 39. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 117(17):9490-6.
dc.citation 40. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J et al.Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582-9.
dc.citation 41. Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790.
dc.citation 42. Özel İÖ. COVID-19 ve konvalesan plazma tedavisi. Atak Yücel A, editör. İmmünoloji ve COVID-19. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.67-72.
dc.citation 43. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759-69.
dc.citation 44. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? microbes and Infection. 2020; 22:72-3.
dc.citation 45. Ulrich H, Pillat MM, Tárnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. Cytometry A. 2020;97(7):662-667.
dc.citation 46. Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly. 2020;150:w20249. doi: 10.4414/smw.2020.20249. PMID: 32298458.


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account